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Abstract 
Cancer diagnosis at an early stage increases the chance of curative treatment and of survival. It has 
been suggested that delays on the pathway from first symptom to diagnosis and treatment may be 
socio-economically patterned, and contribute to socio-economic differences in receipt of treatment 
and in cancer survival. 
This review aimed to assess the published evidence for socio-economic inequalities in stage at 
diagnosis of lung cancer, and in the length of time spent on the lung cancer pathway. MEDLINE, 
EMBASE and CINAHL databases were searched to locate cohort studies of adults with a primary 
diagnosis of lung cancer, where the outcome was stage at diagnosis or the length of time spent 
within an interval on the care pathway, or a suitable proxy measure, analysed according to a 
measure of socio-economic position. Meta-analysis was undertaken when there were studies 
available with suitable data.  
Of the 461 records screened, 39 papers were included in the review (20 from the UK) and seven in a 
final meta-analysis for stage at diagnosis. There was no evidence of socio-economic inequalities in 
late stage at diagnosis in the most, compared to the least, deprived group (odds ratio=1.04, 95% 
confidence interval = 0.92 to 1.19). No socio-economic inequalities in the patient interval or in time 
from diagnosis to treatment were found. 
Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor 
for survival inequalities in cancer. However, socio-economic inequalities in stage at diagnosis were 
not found in a meta-analysis for lung cancer.  
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BACKGROUND 
Cancer patients who are diagnosed at an early stage are more likely to be suitable for receipt of 
potentially curative treatment, thus improving their chances of survival. Length of time to diagnosis 
and treatment has also been associated with cancer survival (1). Delays may lead to diagnosis at a 
later disease stage, resulting in ‘potentially-avoidable’ deaths (2). To address this, the National 
Awareness and Early Diagnosis Initiative (NAEDI) scheme was launched in England, in order to 
encourage early presentation of patients to primary care and to improve general practitioner (GP) 
cancer recognition and referral (2).  
Lung cancer is the most common cancer, worldwide. In the USA and the UK it is the second most 
incident cancer (3, 4), as well as the most common cause of cancer mortality (4, 5). In the UK fewer 
than 10% of those diagnosed with lung cancer survive for 5 years (6).  
A socio-economic gradient for lung cancer survival (7) exists in the UK, which is not fully accounted 
for by the socio-economic gradient in incidence. Socio-economic inequalities in receipt of lung 
cancer treatment have been shown in a recent systematic review and meta-analysis (8) and there is 
some evidence that inequalities in treatment contribute to socio-economic inequalities in lung 
cancer survival (9, 10). It has also been suggested that inequalities in stage at diagnosis and in time 
to diagnosis and treatment might contribute to socio-economic differences in cancer survival (2). 
However, there has been no systematic examination of whether there are socio-economic 
inequalities in stage at diagnosis and time to treatment for lung cancer and where on the pathway 
from symptom-onset to treatment these inequalities might arise.  
This review aimed to investigate whether there are socio-economic inequalities in stage at diagnosis 
for lung cancer, and in the duration of intervals (patient, primary care, referral, diagnosis, treatment) 
on the diagnostic and treatment pathway. 
METHODS/DESIGN 
A protocol was developed, registered with PROSPERO (11) and published (12). Systematic methods 
were used to identify relevant studies, assess study eligibility for inclusion and evaluate study 
quality. The review is reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (13) (see Appendix S1 for PRISMA checklist).  
Search strategy 
A search was undertaken to locate all studies published by the initial search date (Jan 2014), with a 
title and abstract published in English, examining differences, by socio-economic position (SEP), in 
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stage at diagnosis and in patient, primary care, referral, diagnostic and treatment time intervals (and 
combinations thereof) on the care pathway for lung cancer. The searches were re-run in Feb 2016 
and any further studies retrieved for inclusion. 
One researcher (LF) developed the search strategy (File S2), which was refined with the help of an 
Information Scientist and used to search the online databases of MEDLINE, EMBASE and CINAHL. 
The search terms were adapted for the different databases. Additional studies were identified by 
reviewing the reference lists of all included studies and by using a forward citation search to identify 
more recent studies that had cited included studies. EndNote X5 software was used to manage the 
references. 
Study Eligibility 
The following types of study were deemed eligible for inclusion: cohort studies of adult participants 
who had a primary diagnosis of lung cancer (small-cell lung cancer or non-small-cell lung cancer - 
ICD10 C 33 C34); published in a peer-reviewed journal up to the date that the search was run and 
where the outcome was: 
 Stage at diagnosis or stage at the start of treatment (14) [primary outcome]  
 OR mean or median time within an interval on the pathway from first symptom to treatment 
(or a suitable proxy measure of this); Or the likelihood (odds ratio[OR] or hazard ratio [HR] 
with 95% confidence intervals [CI]) of longer or shorter time within an interval on the 
pathway [secondary outcome];   
 And where outcome was analysed by a measure of SEP (an individual or area-based measure 
of deprivation, poverty, income or education). 
 
Time interval definition 
The following four time points have been identified as important markers on the cancer pathway: 
date of first symptom onset, date of first presentation to a health care professional, date of referral 
to secondary/specialist care and date of diagnosis (15).  These and other time points such as date of 
first secondary (specialist) care investigation/first hospital appointment, and date of first treatment 
can be used to define 15 interim time intervals (designated T1-T15) on the pathway from first 
symptom to diagnosis and treatment (16). 
These time intervals can be categorised as follows: patient interval (time from date of first symptom 
to date of first presentation; T1); primary care interval (date of first presentation to date of first 
investigation referral; T6); referral interval (date of GP referral to first specialist appointment or 
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investigation; T10); diagnostic interval (date of secondary care investigation to diagnosis T13); and 
treatment interval (diagnosis to treatment; T15) (12), and combinations thereof. 
The following were included as potential proxy measures of length of time intervals on the pathway; 
type of referral (urgent v routine) (17); emergency presentation (18); diagnosis at death; and 
number of pre-referral consultations (19). 
Stage definition 
Lung cancer stage can be categorised as I, II, III, IV, assigned using the TNM staging system (20). 
Papers which recorded stage at diagnosis or stage at start of treatment in this way, or as early or late 
stage, or as local, regional and distant stage, were considered for inclusion in the stage analysis. 
Study Selection and Data Extraction 
Studies obtained from the database searches were independently assessed by two researchers (LF 
and SS) in three phases: title, abstract and full paper screening,  as detailed in the protocol (12). Any 
disagreements at any of the screening stages were resolved by discussion between the two 
researchers in the first instance. A third reviewer (JA) was available to independently review the 
title, abstract or full paper, if required. 
Data extraction was carried out by LF using a pro-forma based on previous work (8). Data from a 
random sample of 10% of included papers were checked by SS, selected using a random number 
generator.  
Insurance status is an important factor relating to access to lung cancer care in the US healthcare 
system (21) and so may impact on time-intervals on the care pathway. Therefore, as in a previous 
lung cancer systematic review,(8) studies were split into three categories: those carried out in a 
healthcare system free at the point of access (a universal health care system (UHCS) similar to the 
UK); those based on an insurance system (similar to the USA); and those that include a mixture of 
free care and social insurance-based payment (some European systems).  
Study Quality 
A study quality checklist, adapted from existing quality tools (8, 15), was used to divide studies into 
eight quality categories, with 1 being the lowest, and 8 the highest quality (appendix S3). 
Cohort studies reporting only univariable analysis are of lower quality, in terms of their ability to 
control for confounding. Only studies conducting multivariable analysis (quality scores 3-8) were 
considered for meta-analysis.  
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Statistical analysis 
All studies that met the inclusion criteria were included in a narrative synthesis. Studies were 
analysed in three categories: stage at diagnosis, time interval (with sub-group analyses by interim 
intervals), and proxy time interval measures. 
Studies were considered eligible for inclusion in meta-analysis if: multivariable analysis was 
conducted (and included control for a minimum of age and sex as confounders); OR/HRs and 95% CIs 
of likelihood of earlier or later stage at diagnosis or longer or shorter time within an interval on the 
pathway (or a suitable proxy measure of this) in low compared to high SEP were calculated; and SEP 
was not further stratified by another variable.  Sub-group analyses by healthcare system category 
were conducted if two or more comparable studies per system were available.  
Random effects meta-analysis of eligible studies was undertaken using Cochrane Collaboration 
Review Manager 5.1. Natural logs of the ORs and their standard errors (SEs) were calculated for use 
in Forest plots. Where a study reported the most deprived class as the comparator then reverse ORs 
were calculated prior to meta-analysis. The I2 statistic was used to assess heterogeneity. 
Multiple papers using the same or overlapping study data were considered for inclusion. Sensitivity 
analyses were undertaken to examine the effect of including all potentially-eligible studies or only 
high quality studies in meta-analyses. However, only data from the better quality or more detailed 
paper in each overlapping study group were included in the final meta-analyses.  
RESULTS 
A total of 39 papers (14, 18, 22-58) met the inclusion criteria (table S1) and were included in the 
review (PRISMA flow diagram, Figure 1). Twenty papers used data from the UK, 10 from the USA, 2 
from Canada, 2 from Denmark and 1 each from Sweden, Australia, Italy, Korea and New Zealand. 
Twenty nine papers used data from healthcare systems free at point of access and 10 from 
insurance-based systems.  Of the 39 papers, 23 examined stage at diagnosis, 12 examined time 
intervals (three studies looked at both time intervals and stage at diagnosis), and eight examined 
potential proxy measures of delay. Some studies examining stage at diagnosis were suitable for 
meta-analysis.  
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Stage at diagnosis 
Of the 23 studies that examined socio-economic inequalities in stage at diagnosis, 16 studies 
contained data that were unsuitable for meta-analysis (one reported ORs but examined SEP 
subdivided by race, one calculated univariable ORs, and 14 did not calculate odds ratios - nine 
presented unadjusted rates (five with statistical tests) and five presented no numbers (table S4). Of 
these 16 studies, 12 reported or appeared to show no association, and 3 reported an association 
between SEP and stage at diagnosis, but not all in the same direction. One Scottish study (28) found 
that rates of early stage cancer were higher in more deprived patients than less deprived.  Similarly, 
a US study (54) found that college graduates were more likely to be diagnosed with advanced stage 
at diagnosis compared to those without a college degree, but income was not associated with stage. 
However, in contrast, a further US study (36) reported that a higher percentage of more deprived 
patients were diagnosed with later stage cancer (but no numbers presented).  
Eight studies (nine outcomes) conducted multivariable analysis and examined the likelihood (OR) of 
later (or earlier stage) at diagnosis by a marker of SEP and so were considered for meta-analysis 
(table S5). Of these, two studies looked at the same population and one study looked at the same 
outcome using two different measures of SEP (education and income). Seven studies (seven 
outcomes) with non-overlapping populations were selected for the final meta-analysis.  
Overall, there was no evidence of socio-economic inequalities in late stage at diagnosis in the most, 
compared to the least, deprived groups (n=7, odds ratio=1.04, 95% confidence interval = 0.92 to 
1.19) (Fig 2). In sub-group analysis by healthcare system, although there was no evidence of 
differences by SEP in UHCS, there was some suggestion that more deprived patients were likely to 
present with more advanced stage cancer in non-UHCS, although only 2 studies were included. 
Sensitivity analyses including all studies with overlapping populations, utilising a different measure 
of SEP, or different combinations of these, also found no association (appendix S6).  
Time intervals 
Twelve studies examined inequalities within eight of the 15 time intervals. No studies were found 
that examined the intervals from symptom onset to FHA (T3) or to treatment (T5) or from patient 
presentation to GP referral, FHA, diagnosis or treatment (T6-T9), or FHA to treatment (T14). 
Summary interval results are shown in Fig 3 and detailed results for each interval presented in 
supplementary tables 7-10. 
Two studies examined the time from symptom recognition to presentation (T1 patient interval). 
Socioeconomic position was not associated with length of patient interval in any of these (table S7). 
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The intervals from first symptom to GP referral (T2), and to diagnosis (T4), were examined in one 
study, and again no socio-economic inequalities in time intervals were found (table S7).  
Two studies examined the referral interval (T10). One found socioeconomic inequalities in time from 
GP referral to FHA with more deprived patients less likely to have a FHA within 14 days of referral, 
using cancer registry data. The other used self-reported patient survey data and no association 
between referral interval and SEP was found (table S8).  
Four studies (10 outcomes) examined time from GP referral to diagnosis (T11; table S8). In one 
study, the more highly educated (2 outcomes) were less likely to have delayed diagnosis but no 
association was found with income (2 outcomes). The other good quality study found no association 
and the remaining two studies only reported univariable analyses and did not clearly report tests of 
statistical significance. One of these analysed data from early and late stage patients separately: 
more deprived early stage patients had longer time from referral to diagnosis than less deprived 
patients (32 compared to 17 days, although no formal statistical tests were reported). No difference 
in the time between referral to diagnosis between more and less deprived patients with late stage 
disease were found. 
Two studies examined socioeconomic inequalities in time from GP referral to treatment (T12) but 
none were found (table S8).  
Three studies examined time from FHA to diagnosis and none found an association with SEP (T13; 
table S9). Five studies (eight outcomes) examined socioeconomic inequalities in time from diagnosis 
to treatment (T15) but inequalities in the treatment interval were not found (table S10). 
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Other measures  
Eight studies looked at the following measures that might be considered as consequences of delay: 
acute presentation, emergency admission, number of times to consult, and diagnosis at death. More 
deprived patients were more likely to present and to be admitted as an emergency, but socio-
economic inequalities were not found in number of times to consult or in diagnosis at death (table 
S11). 
DISCUSSION 
Principal Findings 
This is the first systematic review to explore socio-economic inequalities in stage at diagnosis and in 
duration of intervals on the diagnostic and treatment pathway of lung cancer. Thirty nine studies 
met the inclusion criteria, 23 examined stage at diagnosis (eight of which were suitable for meta-
analysis), 12 examined time intervals, and eight examined proxy measures of delay. There was no 
evidence of socio-economic inequalities in late stage at diagnosis in the most, compared to the least, 
deprived group overall and in studies from countries with UHCSs. However, there was evidence that 
more deprived patients were more likely to present as emergencies. There was some suggestion of 
socio-economic inequalities in stage at diagnosis in studies from countries with non-UHCSs with 
those in more deprived groups more likely to be diagnosed at late stage than others. No evidence of 
socio-economic inequalities in the patient or treatment intervals were found, and no consistent 
pattern was observed in diagnostic or referral intervals. No studies examined the primary care 
interval. 
Interpretation of results and comparison to previous findings 
Surgery with curative intent is only suitable for early stage lung cancer patients (59) and if patients 
with lower SEP are more likely to present later, and with later stage disease, this may help explain 
known socioeconomic inequalities in receipt of lung cancer surgery (8). In this review, however, 
presentation with later stage lung cancer in more deprived patients was not seen and so inequalities 
in stage at diagnosis cannot explain inequalities in surgery. This concurs with results from our review 
on socioeconomic inequalities in lung cancer treatment, where the association between SEP and 
receipt of surgery was independent of stage at diagnosis. When receipt of treatment was examined 
in studies of early-stage patients only, low SEP remained associated with reduced likelihood of 
surgery (8).  
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Diagnostic delay has been implicated as a factor that contributes to the poorer survival of UK cancer 
patients compared to the European average (2). However, the impact of delay on lung cancer 
survival is unclear (60) and some studies suggest that those who experience shorter system delay 
may have poorer lung cancer survival  as they are clinically “sicker”, with more obvious symptoms 
that result in urgent referral, diagnosis and treatment (1). More deprived patients have been shown 
to have higher comorbidity (34). A recent UK study, which found that lung cancer patients who were 
more clinically unwell were referred, diagnosed and treated more quickly, suggested that this ‘sicker 
quicker’ effect may act to effectively cancel out socio-economic related delays that might otherwise 
result in longer time intervals for more deprived patients (34). Very few of the studies included in 
this current review took account of patient health status when examining time intervals and lack of 
control for this major confounder may mask any inequalities that are present. 
 Strengths and weaknesses of the review and of the available evidence 
No previous reviews have systematically assessed socioeconomic inequalities in stage at diagnosis 
and in time intervals on the lung cancer care pathway and few have considered equity in a meta-
analysis. Extensive searches were carried out to identify studies in the published literature. However, 
it is possible that not all relevant studies were obtained. 
Although a number of studies examined stage at diagnosis, very few good quality studies examined 
comparable intervals on the lung cancer diagnostic and treatment pathway, meaning that meta-
analysis was only possible for studies examining stage at diagnosis. The included studies reported 
observational data only. The suitability of meta-analysis for observational studies has been 
questioned, as it may produce precise but spurious results (61). Heterogeneity can be considered 
high at >50% (62). Study heterogeneity was taken into account. Separate analyses by healthcare 
system type were carried out and different effects were found. 
There was population overlap between some datasets. We attempted to include only substantially 
non-overlapping datasets within the final meta-analysis to ensure independence of results. A 
judgement had to be made as to which was the best quality and most appropriate paper to include, 
but sensitivity analyses using different inclusion combinations (Appendix a) did not change the 
overall findings and nor did including all suitable studies, regardless of population overlap. 
A number of different measures of SEP were used in included studies. These likely categorise 
different people, and different proportions of the population, into the most and least deprived 
groups, meaning that similar populations are not always being compared across studies. This is a 
recognised problem in equity reviews (8). Most UK studies employ deprivation-index measures of 
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SEP, whereas US-based studies rely more on income-based measures.  However, across all included 
cases, area-based measures of SEP were common. These may not accurately reflect individual-level 
circumstances (63) leading to error, and possible bias. This may mean we have under-estimated the 
strength of the true association between SEP and both stage and intervals. Many included studies 
used cohort or cancer registry data not specifically collected to study socio-economic inequalities, 
meaning that authors of studies included in the review were working with the best available data for 
secondary analysis. Effort should be made to ensure household, or individual-level, markers of SEP 
are included in cohort studies and cancer registry datasets to facilitate future analyses. 
In the UK only around 20% of patients are diagnosed at an early stage and so the meta-analysis may 
be underpowered to detect differences between early and late stage presentation by SEP. 
In order to conduct meta-analysis it is necessary to compare the odds of advanced stage at diagnosis 
in the most versus the least deprived groups. This necessarily simplifies what may be a complex 
relationship across SEP groups. The ORs used in the meta-analyses were not consistently adjusted 
for the same covariates.  However, we attempted to take this into account in the quality scores and 
by conducting subgroup sensitivity analyses. Examining only high quality studies did not alter 
findings nor did other sensitivity analyses. It may be useful to develop clear guidance on what 
variables should and should not be adjusted for in future analyses to ensure comparability of 
findings. 
Having been unable to find a suitable tool for assessing cohort study quality for a previous review, 
we created our own. Here we adapted our previously developed tool (8) to produce a unique tool 
that is highly specific to detect bias in the type of study included, considering representativeness of 
the sample, measure of independent and outcome variables and confounder adjustment. It is similar 
to a bias assessment checklist tool developed independently in the interim by another review group 
examining time to diagnosis and treatment in cancer (16). 
Many of the studies included in the narrative review were not of high quality. Many studies used 
routine data which rely on accurate routine recording of dates and others included self-report of 
time intervals, which may suffer from recall bias. There is a possibility of ascertainment bias where 
sicker patients may be less likely to have stage data recorded. The ‘waiting time paradox’ where 
sicker patients progress more quickly through the care pathway as they appear more ill (1) was not 
well accounted for and this may mask any true socio-economic inequalities in time intervals (34). 
Lack of consideration of this is a major limitation in the included studies and makes it difficult to 
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draw firm conclusions. Future investigators should routinely include adjustment for patient health 
status. 
Publication bias is a possibility that needs to be considered for any systematic review, as studies 
reporting null findings may be less likely to be published or, if published, to report numerical 
outcomes (62). However, as the majority of the results reported for this review support the null 
hypothesis, further unreported null results would not change the findings.  
Implications for policy and practice 
No inequalities in the patient interval (from symptom recognition to presentation) or in stage at 
diagnosis were found in this review. There is no current evidence that more deprived patients wait 
longer to consult or present with later stage lung cancer. Therefore there is no indication that 
campaigns to improve early diagnosis need to be targeted at specific socio-economic groups. Rather 
that these need to be aimed at everyone with symptoms that might potentially indicate lung cancer. 
However, as more deprived groups have a higher incidence of lung cancer it may still be prudent to 
target campaigns at these groups.  
Results for the referral and diagnostic intervals were inconclusive but there was some suggestion of 
inequalities within these intervals. This could be indicative of clinical bias where, in countries with 
gatekeeping systems, primary care providers may be more actively referring more affluent patients. 
Alternatively, patient ability to navigate through the referral process may vary by SEP (34, 64).  
Future Research 
Although reducing the time to diagnosis and treatment may have important psychological 
implications for all patients (16), evidence for socio-economic inequalities in time to treatment was 
not found. However, many studies did not take factors such as cancer stage and health status into 
account. Better quality studies that attempt to overcome the ‘sicker quicker’ effect by accounting for 
health status and examining early stage patients separately are required, to more clearly determine 
whether inequalities are present. 
Socio-economic inequalities in stage at diagnosis have been suggested as an important explanatory 
factor for survival inequalities in cancer (2). However, socio-economic inequalities in stage at 
diagnosis for lung cancer were not found in UHCSs in the meta-analysis conducted in this review and 
nor was there good evidence for inequalities in time spent on the care pathway. Previous research 
suggests that socio-economic inequalities in lung cancer treatment rather than in time to treatment 
might help explain socio-economic inequalities in lung cancer survival (10). Further investigation of 
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the patient, tumour and system factors that are important determinants of treatment inequalities is 
required.  
CONCLUSIONS 
There is no clear evidence of socio-economic inequalities in stage at diagnosis or time spent within 
intervals on the symptom to treatment pathway for lung cancer. However, the quality of evidence 
available is significantly limited by the failure of most studies to adjust for important potential 
confounders. Results from this review would suggest that inequalities in time to treatment or in 
stage at diagnosis are unlikely to account for known socio-economic inequalities in receipt of 
treatment for, and survival from, lung cancer in UHCSs, but may be present in non-UHCSs.  
 
What is the key question? 
Are there socio-economic inequalities in stage at diagnosis for lung cancer, and in the length of time 
spent on the lung cancer pathway from symptom onset to treatment? 
What is the bottom line? 
There was no evidence of socio-economic inequalities in late stage at diagnosis in the most, 
compared to the least, deprived group nor of inequalities in the patient or treatment intervals, and 
no consistent pattern was observed in diagnostic or referral intervals.  
Why read on? 
Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor 
for survival inequalities in cancer. This is the first study to systematically explore the evidence for 
inequalities in stage at diagnosis for lung cancer.  
 
FIGURE LEGENDS 
Figure 1: PRISMA flow diagram 
Figure 2. Likelihood of advanced stage at diagnosis in lowest compared to highest SEP group, by 
healthcare system and overall 
Figure 3: Summary of the review findings for each interval 
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